Nondopaminergic mechanisms in levodopa-induced dyskinesia

被引:162
作者
Brotchie, JA [1 ]
机构
[1] Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada
关键词
levodopa-induced dyskinesia; globus pallidus; subthalamic nucleus; postsynaptic signaling; basal ganglia circuitry;
D O I
10.1002/mds.20612
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It has become increasingly apparent that Parkinson's disease involves many transmitter systems other than dopamine. This nondopaminergic involvement impacts on the generation of symptoms, on the neurodegenerative process, but, most tellingly, in the generation of side effects of current treatments, in particular, levodopa-induced dyskinesia (LID). Such mechanisms contribute not only to the expression of LID once it has been established but also to the mechanisms responsible for the development, or priming, of the dyskinetic state and the subsequent maintenance of the brain in that primed state. Within the basal ganglia, abnormalities in different nondopaminergic components of the circuitry have been defined in LID. In particular, a role for enhanced inhibition of basal ganglia outputs by the GABAergic direct pathway has been suggested as a basic mechanism generating LID. We speculate that the external globus pallidus and subthalamic nucleus may play distinct roles in different forms of dyskinesia, e.g., chorea/dystonia; peak/diphasic/off. At the cellular level, an appreciation of abnormal signaling by, among others, glutamatergic (NMDA and AMPA receptors in particular), alpha(2) adrenergic, serotonergic (5HT), cannabinoid and opioid mechanisms in both priming and expression of LID has begun to emerge over the last decade. This is being consolidated, though in many cases questions remain regarding the specific sites of such abnormality within the circuitry. Very recently, at the molecular level, mechanisms controlling neurotransmitter release and impacting on the ability of neurons to maintain particular forms of firing patterning and synchronization, e.g., SV2A, have been identified. This increased understanding has already delivered and will continue to define novel approaches to treatment that target both pre- and postsynaptic signaling molecules throughout the basal ganglia circuitry. (c) 2005 Movement Disorder Society.
引用
收藏
页码:919 / 931
页数:13
相关论文
共 140 条
[51]   Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease [J].
Hallett, PJ ;
Dunah, AW ;
Ravenscroft, P ;
Zhou, S ;
Bezard, E ;
Crossman, AR ;
Brotchie, JM ;
Standaert, DG .
NEUROPHARMACOLOGY, 2005, 48 (04) :503-516
[52]   Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease [J].
Henry, B ;
Crossman, AR ;
Brotchie, JM .
EXPERIMENTAL NEUROLOGY, 1998, 151 (02) :334-342
[53]   Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease [J].
Henry, B ;
Duty, S ;
Fox, SH ;
Crossman, AR ;
Brotchie, JM .
EXPERIMENTAL NEUROLOGY, 2003, 183 (02) :458-468
[54]   μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease [J].
Henry, B ;
Fox, SH ;
Crossman, AR ;
Brotchie, JM .
EXPERIMENTAL NEUROLOGY, 2001, 171 (01) :139-146
[55]   Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat [J].
Henry, B ;
Crossman, AR ;
Brotchie, JM .
EXPERIMENTAL NEUROLOGY, 1999, 155 (02) :204-220
[56]  
Henry B, 1999, MOVEMENT DISORD, V14, P744, DOI 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO
[57]  
2-7
[58]   Levetiracetam interferes with the L-dopa priming process in MPTP-lesioned drug-naive marmosets [J].
Hill, MP ;
Brotchie, JM ;
Crossman, AR ;
Bezard, E ;
Michel, A ;
Grimée, GE ;
Klitgaard, H .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (04) :171-177
[59]   Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease [J].
Hill, MP ;
Ravenscroft, P ;
Bezard, E ;
Crossman, AR ;
Brotchie, JM ;
Michel, A ;
Grimée, R ;
Klitgaard, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01) :386-394
[60]   Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset [J].
Hill, MP ;
Bezard, E ;
McGuire, SG ;
Crossman, AR ;
Brotchie, JM ;
Michel, A ;
Grimée, R ;
Klitgaard, H .
MOVEMENT DISORDERS, 2003, 18 (11) :1301-1305